Dimethylaluminiumcyanid | 5838-54-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Dimethylaluminiumcyanid
• 英文别名: Cyanodimethylaluminum；dimethylalumanylformonitrile
• CAS: 5838-54-0
• 化学式: C₃H₆AlN
• 分子量: 83.0689
• InChiKey: OZQKIUFSEGROHA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  5
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (3S,3aR,7aS)-3a-(Benzhydryl-dimethyl-silanyl)-3-(tert-butyl-dimethyl-silanyloxy)-octahydro-isoindol-1-one 、 Dimethylaluminiumcyanid 在 三氟甲磺酸三甲基硅酯 作用下， 以 二氯甲烷 为溶剂， 以33%的产率得到(1R,3aR,7aS)-7a-(Benzhydryl-dimethyl-silanyl)-3-oxo-octahydro-isoindole-1-carbonitrile
  参考文献：
  名称：

  Stereoselective Synthesis of Highly Substituted γ-Lactams by the [3+2] Annulation of α-Siloxy Allylic Silanes with Chlorosulfonyl Isocyanate

  摘要：

  A stereoselective synthesis of gamma-lactams by the [3+2] annulation of alpha-siloxy allylic silanes with N-chlorosulfonyl isocyanate (CISO2NCO) was developed. The use of these allylic silanes allowed for further diastereoselective substitution of the resultant N,O-acetal to give highly substituted gamma-lactams. Oxidation of the silyl group afforded access to complex beta-hydroxy-gamma-lactams.

  DOI：

  10.1021/ol060596g

文献信息

• HEPATITIS B ANTIVIRAL AGENTS
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20170253609A1

  公开（公告）日：2017-09-07

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了以下式(I)的化合物，或其药学上可接受的盐、酯或前药： X-A-Y-L-R  (I) 这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰HBV生命周期的功能，并且还可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• Reactions of glycosyl fluorides. Synthesis of C-glycosides
  作者：K. C. Nicolaou、Roland E. Dolle、Alexander Chucholowski、Jared L. Randall

  DOI：10.1039/c39840001153

  日期：——

  Glycosyl fluorides were found to react with a number of nucleophilic reagents with or without catalysis leading to a variety of C-glycosides and related compounds.

  发现糖基氟化物在催化作用或不催化作用下与许多亲核试剂反应，从而导致多种C-糖苷和相关化合物。
• Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing
  申请人：Serrano Marugan Manuel

  公开号：US09993554B2

  公开（公告）日：2018-06-12

  The first aspect of the invention relates to a phosphoinositide 3-kinase inhibitor for use in the treatment or prevention of a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-α (Pgd1α) and/or uncoupling protein 1 (Thermogenin/Ucp1) in brown adipocytes. The disease or condition may be positive energy imbalance-associated, for example, obesity, an obesity-associated disease or condition, steatosis and biological aging (performance aging). Another aspect of the invention provides the use of a phosphoinositide 3-kinase inhibitor for promoting weight loss in an individual.

  该发明的第一个方面涉及一种磷脂酰肌醇3-激酶抑制剂，用于治疗或预防与棕色脂肪细胞中过氧化物酶体增殖物激活受体γ共激活因子1-α（Pgd1α）和/或解偶联蛋白1（热原蛋白/Ucp1）表达相关的疾病或病况。该疾病或病况可能与正能量失衡相关，例如肥胖、肥胖相关疾病或病况、脂肪肝和生物老化（性能老化）。该发明的另一个方面提供了使用磷脂酰肌醇3-激酶抑制剂促进个体体重减轻的方法。
• Asymmetric Synthesis of an Advanced Tetracyclic Framework of (+)-Sarain A
  作者：Yu Wang、Lingying Leng、Ying Liu、Guiying Dai、Fanglin Xue、Zhihao Chen、Jiao Meng、Guohua Wen、Yaxin Xiao、Xiao-Yu Liu、Yong Qin

  DOI：10.1021/acs.orglett.8b02779

  日期：2018.11.2

  An asymmetric synthetic approach to a tetracyclic framework of the marine-derived alkaloid (+)-sarain A has been developed. The key steps to constructing the congested diazatricycloundecane core include an asymmetric Diels–Alder cycloaddition, an Ireland–Claisen rearrangement, and an intramolecular aziridination/ring-opening sequence.

  已开发出一种不对称合成方法，用于海洋衍生生物碱（+）-sarain A的四环骨架。构建拥挤的二氮杂三环十一烷核心的关键步骤包括不对称的Diels-Alder环加成反应，Ireland-Claisen重排以及分子内叠氮/开环序列。
• NEEF, GUNTER;VIERHUFE, HARRY;AST, GERHARD
  作者：NEEF, GUNTER、VIERHUFE, HARRY、AST, GERHARD

  DOI：——

  日期：——